Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Capital Expenditures (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Capital Expenditures for 7 consecutive years, with $11.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 35.18% to $11.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was $14.0 million, a 51.0% increase, with the full-year FY2025 number at $14.0 million, up 51.0% from a year prior.
  • Capital Expenditures was $11.9 million for Q4 2025 at Nurix Therapeutics, up from -$4.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $11.9 million in Q4 2025 to a low of -$8.3 million in Q4 2022.
  • A 5-year average of $1.5 million and a median of $1.7 million in 2023 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 311.86% in 2022; the steepest drop was 1063.57% in 2022.
  • Nurix Therapeutics' Capital Expenditures stood at $862000.0 in 2021, then crashed by 1063.57% to -$8.3 million in 2022, then soared by 37.59% to -$5.2 million in 2023, then surged by 269.56% to $8.8 million in 2024, then soared by 35.18% to $11.9 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Capital Expenditures are $11.9 million (Q4 2025), -$4.0 million (Q3 2025), and $2.7 million (Q2 2025).